This April at Owlstone Medical
From new research partnerships to press coverage and conference preparation, March has been another busy month for Owlstone. Excitingly, we’ve also just launched our new gut health-focused brand, OMED Health, so read on to find out more!
New partnership with Bicycle Therapeutics
In March, we entered a new research partnership with biotechnology company, Bicycle Therapeutics plc, to explore the potential of combining our EVOC? probes with their proprietary bicyclic peptide (Bicycle?) technology for the early detection of cancer. Through this partnership, we hope to enhance the performance of these innovative technologies for use in pre-clinical research, clinical trials, and beyond.
The launch of OMED Health
This month we are delighted to announce the launch of the OMED Health waitlist. As mentioned in a previous newsletter, OMED Health will offer at-home breath-based tests, point-of-care devices, and support resources for a range of gastrointestinal conditions to help people take control of their digestive health. Those living with gut health discomfort can already order our hydrogen methane breath tests here and you can sign up for our waitlist now to get priority access to the OMED Health Breath analyzer and App, or follow us on Facebook and Instagram to keep up-to-date with news and updates.
Owlstone features in Drug Discovery News Article
We are excited to see that our presence and prominence in the breath research field have been recognized in an article in Drug Discovery News. We believe that our technology has the potential to revolutionize the early detection of disease, and the coverage of our EVOC? probes and new VOC Atlas is a testament to the growing interest in using breath samples for disease screening, diagnosis, and management. You can read more about the feature on our website.
Owlstone on tour
A contingent from Owlstone’s UK and US teams will be jetting off to Orlando, Florida to attend the American Association for Cancer Research Annual Meeting from April 14-19th. Dr Ace Hatch, Senior Biomarker Scientist, will be presenting a poster on lung cancer detection using β-glucuronidase targeting EVOC? probes in the Diagnostic and Prognostic Biomarkers session on April 17th. You will be able to meet some of our expert team at booth 3076. Get in touch if you’re attending the AACR Annual Meeting too, we’d love to see you there!
If you have any questions, feel free to get in touch here on LinkedIn or via our website.
